GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (FRA:0L8) » Definitions » Price-to-Owner-Earnings

Lantheus Holdings (FRA:0L8) Price-to-Owner-Earnings : 16.74 (As of May. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Price-to-Owner-Earnings?

As of today (2024-05-15), Lantheus Holdings's share price is €71.66. Lantheus Holdings's Owner Earnings per Share (TTM) ended in Mar. 2024 was €4.28. It's Price-to-Owner-Earnings for today is 16.74.


The historical rank and industry rank for Lantheus Holdings's Price-to-Owner-Earnings or its related term are showing as below:

FRA:0L8' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.95   Med: 21.51   Max: 85.84
Current: 16.83

During the past 13 years, the highest Price-to-Owner-Earnings of Lantheus Holdings was 85.84. The lowest was 8.95. And the median was 21.51.


FRA:0L8's Price-to-Owner-Earnings is ranked better than
69.93% of 419 companies
in the Drug Manufacturers industry
Industry Median: 28.45 vs FRA:0L8: 16.83

As of today (2024-05-15), Lantheus Holdings's share price is €71.66. Lantheus Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €6.06. Therefore, Lantheus Holdings's PE Ratio for today is 11.83.

As of today (2024-05-15), Lantheus Holdings's share price is €71.66. Lantheus Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was €4.86. Therefore, Lantheus Holdings's PE Ratio without NRI for today is 14.73.

During the past 13 years, Lantheus Holdings's highest PE Ratio without NRI was 237.26. The lowest was 5.98. And the median was 21.08.


Lantheus Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for Lantheus Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Price-to-Owner-Earnings Chart

Lantheus Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.31 - - - 30.38

Lantheus Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 30.38 13.45

Competitive Comparison of Lantheus Holdings's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's Price-to-Owner-Earnings falls into.



Lantheus Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Lantheus Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=71.66/4.28
=16.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantheus Holdings  (FRA:0L8) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Lantheus Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings (FRA:0L8) Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings (FRA:0L8) Headlines

No Headlines